>>BOSTON--(BUSINESS WIRE)--Jan. 9, 2002-- Boston Life Sciences, Inc. (NASDAQ:BLSI - news) announced that its lead anti-cancer compound Troponin I, when administered by constant infusion in extremely low doses to mice, dramatically suppressed growth of melanoma metastases in the lung. These results, part of the Company's finalization of dosage protocol for the upcoming human clinical trials of Troponin, continue to strongly suggest that Troponin has superior potential as a clinically effective anti-angiogenic product for the prevention of tumor metastases in high-risk cancer patients, the Company said.
The study, carried out at the McGill Center for Transnational Research in Cancer at the Jewish General Hospital in Montreal, consisted of administering the Company's clinical formulation of GMP Troponin to mice beginning 24 hours after intravenous introduction of B16 melanoma cells into the animals. These melanoma cells localize in the lung within several hours after injection and require the establishment of a vascular blood supply in order to grow to a size that is visible to the naked eye. The mice were treated with a constant intravenous infusion of Troponin at a cumulative dose of either 1 or 5mg/kg/day. Animals were sacrificed after 24 days of treatment. Animals receiving 1 mg/kg/day of Troponin had an approximate 65% decrease in the number of lung metastases compared to control, and animals receiving 5mg/kg/day had a greater than 90% decrease in the number of metastases compared to control.
``In reviewing the published studies of other anti-angiogenic experiments utilizing this standard model, we could not find any results that come close to this degree of metastatic tumor suppression,'' stated Dr. Marc Lanser, MD, Chief Scientific Officer of BLSI. ``Consistent with the growing consensus in the field, we found that constant intravenous infusion of Troponin at very low doses results in a dramatic reduction in metastatic tumor growth. These doses, when extrapolated to the quantity of Troponin we currently plan to use in our upcoming human trial, are 1/100th or less of the doses currently being used in human clinical studies with other anti-angiogenic proteins. Consequently, we believe that what we have seen in the pre-cilinical results of our lead compound bodes very well for the potential success of Troponin in humans,'' added Dr. Lanser.
The Company plans to file an Investigational New Drug (IND) application for the use of Troponin in cancer patients with a high-risk of developing metastases during the first quarter of 2002.<<
snip
Good for a 10% pop into the 3s.
Cheers, Tuck |
